FATE THERAPEUTICS INC Payments to Acquire Investments
FATE THERAPEUTICS INC (FATE) reported Payments to Acquire Investments of $87.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-13
- FATE THERAPEUTICS INC payments to acquire investments for the quarter ending 2026-06-30 was $58.35M, a 14.82% increase year-over-year.
- FATE THERAPEUTICS INC payments to acquire investments for the quarter ending 2026-03-31 was $28.73M, a 40.92% decline year-over-year.
- FATE THERAPEUTICS INC payments to acquire investments for the quarter ending 2025-12-31 was $37.73M, a 0.72% decline year-over-year.
- FATE THERAPEUTICS INC payments to acquire investments for the quarter ending 2025-09-30 was $57.98M, a 10.46% decline year-over-year.
- FATE THERAPEUTICS INC payments to acquire investments for fiscal 2025 was $195.14M, a 38.59% decline from fiscal 2024.
- FATE THERAPEUTICS INC payments to acquire investments for fiscal 2024 was $317.75M, a 11.44% decline from fiscal 2023.
- FATE THERAPEUTICS INC payments to acquire investments for fiscal 2023 was $358.81M, a 11.36% decline from fiscal 2022.
- FATE THERAPEUTICS INC payments to acquire investments for fiscal 2022 was $404.80M, a 58.19% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $87.08M 10-Q · filed 2026-08-13 | $124.81M derived: sum of 3 quarters · filed 2026-08-13 | $182.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $28.73M 10-Q · filed 2026-05-13 | $66.46M derived: sum of 2 quarters · filed 2026-05-13 | $124.44M derived: sum of 3 quarters · filed 2026-05-13 | $175.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $37.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $95.71M derived: sum of 2 quarters · filed 2026-02-26 | $146.52M derived: sum of 3 quarters · filed 2026-08-13 | $195.14M 10-K · filed 2026-02-26 |
| 2025-09-30 | $57.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $108.79M derived: sum of 2 quarters · filed 2026-08-13 | $157.41M 10-Q · filed 2025-11-13 | $195.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $50.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $99.44M 10-Q · filed 2026-08-13 | $137.44M derived: sum of 3 quarters · filed 2026-08-13 | $202.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $48.62M 10-Q · filed 2026-05-13 | $86.63M derived: sum of 2 quarters · filed 2026-05-13 | $151.37M derived: sum of 3 quarters · filed 2026-05-13 | $280.04M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $38.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $102.75M derived: sum of 2 quarters · filed 2026-02-26 | $231.41M derived: sum of 3 quarters · filed 2026-02-26 | $317.75M 10-K · filed 2026-02-26 |
| 2024-09-30 | $64.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $193.41M derived: sum of 2 quarters · filed 2025-11-13 | $279.75M 10-Q · filed 2025-11-13 | $329.71M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $128.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $215.00M 10-Q · filed 2025-08-12 | $264.97M derived: sum of 3 quarters · filed 2025-08-12 | $367.10M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $86.33M 10-Q · filed 2025-05-13 | $136.30M derived: sum of 2 quarters · filed 2025-05-13 | $238.43M derived: sum of 3 quarters · filed 2025-05-13 | $330.69M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $49.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $152.10M derived: sum of 2 quarters · filed 2025-03-05 | $244.36M derived: sum of 3 quarters · filed 2025-03-05 | $358.81M 10-K · filed 2025-03-05 |
| 2023-09-30 | $102.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $194.39M derived: sum of 2 quarters · filed 2024-11-12 | $308.84M 10-Q · filed 2024-11-12 | $415.95M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $92.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $206.71M 10-Q · filed 2024-08-13 | $313.82M derived: sum of 3 quarters · filed 2024-08-13 | $415.39M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $114.45M 10-Q · filed 2024-05-09 | $221.55M derived: sum of 2 quarters · filed 2024-05-09 | $323.13M derived: sum of 3 quarters · filed 2024-05-09 | $387.08M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $107.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $208.68M derived: sum of 2 quarters · filed 2024-02-26 | $272.63M derived: sum of 3 quarters · filed 2024-02-26 | $404.80M 10-K · filed 2024-02-26 |
| 2022-09-30 | $101.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $165.53M derived: sum of 2 quarters · filed 2023-11-08 | $297.69M 10-Q · filed 2023-11-08 | $471.14M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $63.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $196.12M 10-Q · filed 2023-08-08 | $369.56M derived: sum of 3 quarters · filed 2023-08-08 | $535.03M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $132.17M 10-Q · filed 2023-05-03 | $305.61M derived: sum of 2 quarters · filed 2023-05-03 | $471.08M derived: sum of 3 quarters · filed 2023-05-03 | $570.42M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $173.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $338.92M derived: sum of 2 quarters · filed 2023-02-28 | $438.25M derived: sum of 3 quarters · filed 2023-02-28 | $968.16M 10-K · filed 2023-02-28 |
| 2021-09-30 | $165.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $264.81M derived: sum of 2 quarters · filed 2022-11-03 | $794.71M 10-Q · filed 2022-11-03 | $979.72M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $99.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $629.24M 10-Q · filed 2022-08-03 | $814.25M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2021-03-31 | $529.91M 10-Q · filed 2022-05-04 | $714.91M derived: sum of 2 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $185.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $277.34M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $92.34M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $142.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $142.68M derived: sum of 2 quarters · filed 2022-02-28 | $248.86M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $106.18M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $106.18M 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $55.66M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $39.97M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |